Combining a beta2-agonist with a face mask to prevent exercise-induced bronchoconstriction

Area of Science:

• Pulmonology
• Exercise Physiology
• Allergy and Immunology

Background:

• Exercise-induced bronchoconstriction (EIB) is a common condition in asthmatic individuals, particularly when exercising in cold air.
• Current management strategies for EIB may not be fully effective for all patients, especially athletes competing in cold climates.

Purpose of the Study:

• To evaluate the efficacy of combining a P2-agonist medication with a heat- and moisture-exchanging (HME) cellulose face mask in preventing cold-air-induced bronchoconstriction.
• To investigate the combined therapeutic effect on lung function parameters in asthmatic patients.

Main Methods:

• A randomized controlled study involving nine allergic asthmatic patients with a history of exercise-induced adverse reactions.
• Participants underwent exercise challenges on an ergometric bicycle at approximately -10°C under four conditions: no treatment, beta2-agonist premedication, HME face mask use, and combined treatment.
• Lung function, specifically forced expiratory volume in 1 second (FEV1), was measured after each treatment regimen and exercise provocation.

Main Results:

• The greatest decrease in FEV1 (27%) occurred without any treatment.
• Using the HME face mask alone reduced FEV1 decrease to 12%, while beta2-agonist premedication reduced it to 7%.
• No significant decrease in FEV1 was observed when the beta2-agonist and HME face mask were used in combination.

Conclusions:

• The combination of a P2-agonist and an HME face mask provides complete protection against exercise-induced bronchoconstriction in cold air.
• Different pathophysiological mechanisms contribute to EIB, suggesting tailored treatment approaches may be beneficial.
• This combined therapy is highly relevant for asthmatic athletes training and competing in cold environments, where even minor lung function changes can impact performance.